• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Scopus BioPharma's Subsidiary — Duet Therapeutics — Announces Appointment of Marcin Kortylewski, Ph.D. as Senior Scientific Advisor

    9/7/21 9:15:00 AM ET
    $SCPS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SCPS alert in real time by email

    Dr. Kortylewski is the Leading Authority on Bi-Functional Oligonucleotide Cancer Therapeutics and a Professor in the Department of Immuno-Oncology at the Beckman Research Institute at City of Hope National Medical Center

     Dr. Kortylewski to Chair and Present at the 14th Annual RNA Consortium Meeting

    NEW YORK, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: "SCPS"), a clinical-stage biopharmaceutical company developing transformational therapeutics for serious diseases with significant unmet medical need, today announced the appointment of Marcin Kortylewski, Ph.D. as Senior Scientific Advisor of Duet Therapeutics. Duet Therapeutics is a wholly-owned subsidiary of Scopus.

    Dr. Kortylewski is a Professor in the Department of Immuno-Oncology at the Beckman Research Institute at City of Hope National Medical Center. Dr. Kortylewski's research focuses on understanding immune cell dysfunction in tumors and translating those understandings into bi-functional oligonucleotide cancer therapeutics. A significant focus of Dr. Kortylewski and his team is on the development of TLR9- and STAT3-targeted oligonucleotide immunotherapeutics. Dr. Kortylewski's team is responsible for the invention and early development of Duet's three CpG-STAT3 inhibitors.

    Duet Therapeutics was recently launched by Scopus to integrate the immunotherapy assets of Scopus and Olimmune, creating the Duet Platform. Dr. Kortylewski co-founded Olimmune with John Rossi, Ph.D., the Lidow Family Research Chair and Professor of the Department of Molecular and Cellular Biology at City of Hope.

    The Duet Platform is comprised of three distinctive complementary CpG-STAT3 inhibitors:

    • RNA silencing
     CpG-STAT3siRNA ("DUET-01")
    • Antisense
     CpG-STAT3ASO ("DUET-02")
    • DNA-binding inhibitor
     CpG-STAT3decoy ("DUET-03")

    In his new role as Senior Scientific Advisor to Duet, Dr. Kortylewski will continue to provide scientific and other guidance on the development of the three CpG-STAT3 inhibitors constituting the Duet Platform. Dr. Kortylewski served on the Scientific Advisory Board of Scopus prior to Duet's formation.

    Alan Horsager, Ph.D., President and Chief Executive Officer of Duet and President — Immuno-Oncology for Scopus, stated, "We are thrilled to have Dr. Kortylewski on our team as our Senior Scientific Advisor. Dr. Kortylewski has over 20 years of experience in the research and development of cancer immunotherapies and is the leading authority on bi-functional oligonucleotide cancer therapeutics. I have worked closely with Dr. Kortylewski over the last three years and have experienced firsthand his expertise, enthusiasm and confidence relating to the Duet Platform technologies and prospects. Dr. Kortylewski and his lab have been responsible for the discovery and/or early development of each of the three CpG-STAT3 inhibitors that comprise the Duet Platform. As the inventor of the Duet Platform technologies, Dr. Kortylewski is uniquely qualified to advise Duet on their continued development and evolution."

    On Wednesday, September 8, 2021, Dr. Kortylewski will be Chair of the Transcription and Control of Gene Expression session at the 14th Annual RNA Consortium Meeting. On Thursday, September 9, 2021, Dr. Kortylewski will make a presentation entitled Dual-Function Oligonucleotides for Targeting Telomerase and Activation of Antitumor Immunity, as part of the Novel Nucleic Acid Therapeutics session.

    As previously announced, Dr. Horsager will also present at the RNA Consortium Meeting on Friday, September 10, 2021. Dr. Horsager's presentation will be part of the Clinical Translation of Oligonucleotide Therapeutics session. Dr. Horsager will make a presentation entitled Clinical Development of CpG-STAT3 Inhibitors.

    About Scopus BioPharma

    Scopus BioPharma Inc., both directly and through subsidiaries, is a clinical-stage biopharmaceutical company developing transformational therapeutics for serious diseases with significant unmet medical need. The company's lead drug candidate is a novel, targeted immuno-oncology RNA therapy for the treatment of multiple cancers. This drug candidate is highly distinctive, encompassing both RNA therapy and immunotherapy by synthetically linking siRNA to an oligonucleotide TLR9 agonist, creating the potential for targeted gene silencing with simultaneous TLR stimulation and immune activation in the tumor microenvironment. Additional STAT3-targeting immunotherapy drug candidates include bi-functional antisense and DNA-binding inhibition therapies. In addition, the company is developing additional drug candidates that target the endocannabinoid system, including MRI-1867 for the treatment systemic sclerosis. The company also seeks to identify additional compelling technologies for potential acquisition, in-licensing and/or other similar transactions. Receive updates by following Scopus BioPharma on Twitter here.

    Forward-Looking Statements

    This press release may include forward-looking statements that involve risks and uncertainties. Forward-looking statements are statements that are not historical facts. Such forward-looking statements are subject to risks (including those set forth in the company's Form 10-K for the fiscal year ended December 31, 2020, as amended, filed with the U.S. Securities and Exchange Commission ("SEC")) and uncertainties which could cause actual results to differ from the forward-looking statements. The company expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the company's expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based. Investors should realize that if our underlying assumptions for the projections contained herein prove inaccurate or that known or unknown risks or uncertainties materialize, actual results could vary materially from our expectations and projections. Further, there can be no assurance that the company will identify and/or consummate any transaction relating to any additional technologies.

    Contacts

    Rodd Leeds/David Waldman

    Crescendo Communications, LLC

    Tel: (212) 671-1020

    Email: [email protected]

    Hugh Burns/Delia Cannan/Nicholas Leasure

    Reevemark

    Tel: (212) 433-4600

    Email: [email protected]



    Primary Logo

    Get the next $SCPS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SCPS

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $SCPS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Scopus BioPharma's Subsidiary — Duet BioTherapeutics — Presents Compelling New Data for a Novel Treatment for Malignant Glioma at 38th Annual Meeting of the Society for Immunotherapy of Cancer

      DUET-102 in Combination with PD-1 Blockade Demonstrates Significant Anti-Tumor Activity in Models of Malignant Glioma Data Suggests Benefits of Combinations of DUET-102 with Other T-Cell Based Immunotherapies, such as CAR-Ts NEW YORK, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (OTCQB: "SCPS") and its majority-owned subsidiary, Duet BioTherapeutics Inc., presented compelling new data that DUET-102 in combination with PD-1 blockade demonstrates significant anti-tumor activity in models of malignant glioma. The new data was presented on November 4, 2023 at the 38th Annual Meeting of the Society for Immunotherapy of Cancer ("SITC") by Marcin Kortylewski, Ph.D. Dr. Kortylewski,

      11/7/23 9:15:00 AM ET
      $SCPS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Scopus BioPharma's Subsidiary — Duet BioTherapeutics — to Present at the 38th Annual Meeting of the Society for Immunotherapy of Cancer

      NEW YORK, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (OTCQB: "SCPS"), a biotechnology company developing transformational therapeutics for serious diseases with significant unmet medical need, and its subsidiary, Duet BioTherapeutics Inc., which is developing novel immunotherapies to overcome treatment-resistant cancers, today announced that Marcin Kortylewski, Ph.D., Co-Founder and Senior Scientific Advisor of Duet and Professor of Immuno-Oncology at City of Hope, will be presenting at the 38th Annual Meeting of the Society for Immunotherapy of Cancer ("SITC"). SITC is being held from November 3-5, 2023, in San Diego, California. Details of the presentation are as follows:

      11/2/23 9:15:00 AM ET
      $SCPS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Scopus BioPharma's Subsidiary — Duet BioTherapeutics — Announces Key Scientific Data to be Presented at the 37th Annual Meeting and Exposition of the Society for Immunotherapy of Cancer

      NEW YORK, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: "SCPS"), a biopharmaceutical company developing transformational therapeutics for serious diseases with significant unmet medical need, and its pure-play immuno-oncology subsidiary, Duet BioTherapeutics, today announced that key scientific data will be will be presented at the 37th Annual Meeting and Exposition of the Society for Immunotherapy of Cancer ("SITC"). SITC is being held from November 8-12, 2022 at the Boston Convention and Exhibition Center in Boston, Massachusetts. About Scopus BioPharma Scopus BioPharma Inc. is a biopharmaceutical company developing transformational therapeutics for serious diseases

      11/10/22 9:15:00 AM ET
      $SCPS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SCPS
    Financials

    Live finance-specific insights

    See more
    • Scopus BioPharma Expands Immunotherapy Pipeline with Acquisition of Olimmune

      Transaction Creates Global Leader in Oligonucleotide Cancer Therapeutics Combined Assets Target Broad Range of Hematological Malignancies and Solid Tumors NEW YORK, June 30, 2021 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: "SCPS"), a clinical-stage biopharmaceutical company developing transformational therapeutics, today announced the acquisition of Los Angeles-based Olimmune Inc. Olimmune is a developer of groundbreaking oligonucleotide immunotherapies for treatment-resistant and metastatic cancers. Olimmune's lead drug candidate, OLIM-01, is being developed for genitourinary and head and neck cancers. It is anticipated that INDs for these indications will be submitt

      6/30/21 9:30:00 AM ET
      $SCPS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SCPS
    SEC Filings

    See more
    • SEC Form 1-Z filed by Scopus BioPharma Inc.

      1-Z - Scopus BioPharma Inc. (0001772028) (Filer)

      2/9/24 5:15:27 PM ET
      $SCPS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 15-12G filed by Scopus BioPharma Inc.

      15-12G - Scopus BioPharma Inc. (0001772028) (Filer)

      1/19/24 5:15:20 PM ET
      $SCPS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Scopus BioPharma Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

      8-K - Scopus BioPharma Inc. (0001772028) (Filer)

      8/18/23 5:16:15 PM ET
      $SCPS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SCPS
    Leadership Updates

    Live Leadership Updates

    See more
    • Scopus BioPharma Announces Biotechnology Industry Leader Rejoins Board of Directors

      NEW YORK, May 05, 2022 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: "SCPS"), a biopharmaceutical company developing transformational therapeutics for serious diseases with significant unmet medical need, today announced the appointment of Raphael ("Rafi") Hofstein, Ph.D. to its Board of Directors ("Board"). Joshua R. Lamstein, Chairman of Scopus BioPharma, stated, "We are thrilled Dr. Hofstein is rejoining our Board. Dr. Hofstein brings invaluable insights and unparalleled experience in building start-up biotechnology companies into industry leaders." Dr. Hofstein is a global leader in the biopharmaceutical and biotechnology industries. Over his career, Dr. Hofstein has been in

      5/5/22 8:30:00 AM ET
      $SCPS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Scopus BioPharma Provides Update Following Annual Meeting of Stockholders

      Overwhelming Majority of Shares Voted by Unaffiliated Stockholderswere in Favor of Scopus' Director Nominees Lasters' Ownership Position and Annual Meeting Results are being Challenged in Court Company Believes Ultimate Outcome of Annual Meeting Will Depend on Results of Pending Cases NEW YORK, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (NASDAQ:SCPS) ("Scopus" or the "Company") today announced that it has filed an amendment to the Current Report on Form 8-K that was filed by the Company on December 27, 2021 with the U.S. Securities and Exchange Commission disclosing the certified voting results of the Annual Meeting of Stockholders (the "Annual Meeting"). In addition, Scop

      1/10/22 8:30:00 AM ET
      $SCPS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • DR. MORRIS C. LASTER WINS PROXY CONTEST AS STOCKHOLDERS ELECT HIS NOMINEES TO SCOPUS BIOPHARMA INC. BOARD OF DIRECTORS

      NEW YORK and JERUSALEM, Jan. 6, 2022 /PRNewswire/ -- Dr. Morris C. Laster ("Dr. Laster"), who, together with other proxy participants, beneficially owns 6,006,000 shares of common stock, par value $0.001, of Scopus BioPharma Inc. (NASDAQ:SCPS) ("Scopus" or the "Company"), announced today that stockholders of the Company have elected Dr. Laster's two director nominees, Mordechai Saar Hacham and Joshua Levine to the Company's Board of Directors at the Company's 2021 Annual Meeting of Stockholders (the "Annual Meeting"). First Coast Results, Inc., the independent inspector of elections appointed by the Company for the Annual Meeting, today certified the final results of the election reporting t

      1/6/22 7:00:00 AM ET
      $SCPS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SCPS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Greenspan Ira Scott

      4 - Scopus BioPharma Inc. (0001772028) (Issuer)

      11/26/21 5:01:25 PM ET
      $SCPS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Lamstein Joshua R

      4 - Scopus BioPharma Inc. (0001772028) (Issuer)

      11/26/21 5:01:05 PM ET
      $SCPS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Hopper Paul acquired 706,333 shares, increasing direct ownership by 100% to 12,666 units

      4 - Scopus BioPharma Inc. (0001772028) (Issuer)

      11/17/21 9:48:52 AM ET
      $SCPS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SCPS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D filed by Scopus BioPharma Inc.

      SC 13D - Scopus BioPharma Inc. (0001772028) (Subject)

      11/26/21 5:04:51 PM ET
      $SCPS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Scopus BioPharma Inc. (Amendment)

      SC 13D/A - Scopus BioPharma Inc. (0001772028) (Subject)

      11/26/21 5:00:40 PM ET
      $SCPS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Scopus BioPharma Inc. (Amendment)

      SC 13D/A - Scopus BioPharma Inc. (0001772028) (Subject)

      11/26/21 5:00:10 PM ET
      $SCPS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SCPS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Benchmark initiated coverage on Scopus BioPharma with a new price target

      Benchmark initiated coverage of Scopus BioPharma with a rating of Buy and set a new price target of $20.00

      2/16/21 8:08:22 AM ET
      $SCPS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • The Benchmark Company initiated coverage on Scopus BioPharma with a new price target

      The Benchmark Company initiated coverage of Scopus BioPharma with a rating of Speculative Buy and set a new price target of $20.00

      2/16/21 7:40:13 AM ET
      $SCPS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Benchmark initiated coverage on Scopus BioPharma

      Benchmark initiated coverage of Scopus BioPharma with a rating of Buy

      2/16/21 7:25:31 AM ET
      $SCPS
      Biotechnology: Pharmaceutical Preparations
      Health Care